Biocon Limited announced that it has received approval from the Medicines and Healthcare Products Regulatory Agency (MHRA), U.K., for its complex formulation Liraglutide (6mg/ml solution for injection in pre-filled pen), which was filed through its European partner, Zentiva. Liraglutide is a drug-device combination formulation used in the treatment of Type 2 Diabetes Mellitus, a disorder in which the body does not produce enough or respond normally to insulin, causing blood sugar (glucose) levels to be abnormally high.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
306.2 INR | -0.08% | +12.91% | +22.63% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+22.63% | 4.39B | |
-2.63% | 103B | |
+1.62% | 95.28B | |
+1.46% | 22.15B | |
-16.67% | 21.02B | |
-8.58% | 18.15B | |
-38.74% | 16.73B | |
-13.21% | 16.05B | |
+5.41% | 13.68B | |
+33.57% | 12.17B |
- Stock Market
- Equities
- BIOCON Stock
- News Biocon Limited
- Biocon Limited to Obtain Approval for Diabetes Drug, Liraglutide, in the U.K